LifeCare Partners

b-rayZ is a spin-off of the University Hospital Zurich. Their team consists of professional radiologists, data scientists and physicians, with more than 15 years of work experience in medical imaging and radiology. They develop and provide predictive deep learning analytical tools and algorithms for the assessment of your personal medical images.

Developer of prediction platform designed to translate medical data into intelligent predictions to support and optimize clinical decisions. The company's platform supports perinatal, neonatal, and pediatric applications to evaluate, optimize and personalize medical strategies for the care of newborns, enabling medical practitioners to improve and personalize health care in early life and avoid long-term complications.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

Leukocare is a company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation in patients undergoing cardiac surgery. It offers innovative formulation technologies that leverage bioinformatics and artificial intelligence for the improvement of biopharmaceuticals, viral vectors, and vaccines. Additionally, the company specializes in biofunctionalized devices that help decrease leukocyte activity in extracorporeal blood circuits using antibodies. Leukocare intends to utilize its funding to advance market access efforts for several development projects based on its Stabilizing and Protecting Solutions (SPS®) across various fields, including vaccines, biopharmaceuticals, and combination devices.